Alyeska Investment Group
EPRX

Alyeska Investment Group’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Alyeska Investment Group’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.71M Buy
+375,000
New +$3.02M 0.01% 534
2025
Q4 		– Sell
-250,000
Closed -$1.48M – 754
2025
Q3 		$1.48M Buy
+250,000
New +$1.36M ﹤0.01% 522

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Alyeska Investment Group's EPRX Position: Q1 2026 in Review

Alyeska Investment Group opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q1 2026: 375,000 shares worth $2.71M. The stake represents 0.01% of the portfolio and ranks #534 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in EPRX as recently as Q3 2025.

Alyeska Investment Group first reported a position in EPRX in Q3 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Alyeska Investment Group held 375,000 shares of Eupraxia Pharmaceuticals worth $2.71M as of Q1 2026.
  • Eupraxia Pharmaceuticals was a new Alyeska Investment Group position in Q1 2026.
  • Eupraxia Pharmaceuticals made up 0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #534 holding.
  • Alyeska Investment Group first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.